Emergent BioSolutions, Inc., to create more jobs in Lansing, Mich.

A new federal contract awarded to Emergent BioSolutions, Inc., worth as much $186.6 million for the development of a next-generation anthrax vaccine will allow the company to expand the work force at its Lansing, Mich. facilities.

"Anthrax remains the single largest bioterror threat to the United States and this announcement is a down payment on our national commitment to the development of the next generation of anthrax biodefenses," U.S. Rep. Mike Rogers said in a statement.

The Rockville, Maryland-based Emergent BioSolutions, Inc., manufactures the only federally approved anthrax vaccine at its Lansing facilities, which will add 25 new jobs over the course of the next year as a result of the contract, the Lansing State Journal reports.

Emergent BioSolutions, Inc., announced the new contract with the U.S. Department of Health and Human Services on Friday. The contract is worth $51 million during its first two years, with an option for three additional years.

The next-generation vaccine will reportedly be manufactured at the company's Maryland facility, according to the Lansing State Journal, but Adam Havey, president of Emergent BioSolutions, Inc.'s Lansing operations, has said that a manufacturing site has not yet been determined.

Regardless of the manufacturing site, Havey told the Lansing State Journal, highly technical jobs related to the contract will be brought to Lansing. The contract could result in the creation of as many as 50 jobs in the city.

Emergent BioSolutions, Inc., currently employs more than 400 people in Lansing, a slight increase from its approximately 340 employees at the end of 2008. As part of a $3 million incentive package announced in Marc 2009, the company has promised to add 93 new jobs over the course of five years.